<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" href="https://www.taxtmi.com/rss_sitemap/rss_feed_blog.xsl?v=1750492856"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>2022 (1) TMI 740 - BOMBAY HIGH COURT</title>
    <link>https://www.taxtmi.com/caselaws?id=417275</link>
    <description>The High Court upheld the Tribunal&#039;s decision, emphasizing the non-retrospective application of Circular No.5 of 2012 to pharmaceutical companies and the lack of legal prohibition on such expenses. The judgment provided clarity on the interpretation of tax laws concerning pharmaceutical companies&#039; expenditures on medical practitioners, setting a precedent for future cases.</description>
    <language>en-us</language>
    <pubDate>Fri, 14 Jan 2022 00:00:00 +0530</pubDate>
    <lastBuildDate>Thu, 28 Apr 2022 17:20:00 +0530</lastBuildDate>
    <generator>TaxTMI RSS Generator</generator>
    <atom:link href="https://www.taxtmi.com/rss_feed_blog?id=667611" rel="self" type="application/rss+xml"/>
    <item>
      <title>2022 (1) TMI 740 - BOMBAY HIGH COURT</title>
      <link>https://www.taxtmi.com/caselaws?id=417275</link>
      <description>The High Court upheld the Tribunal&#039;s decision, emphasizing the non-retrospective application of Circular No.5 of 2012 to pharmaceutical companies and the lack of legal prohibition on such expenses. The judgment provided clarity on the interpretation of tax laws concerning pharmaceutical companies&#039; expenditures on medical practitioners, setting a precedent for future cases.</description>
      <category>Case-Laws</category>
      <law>Income Tax</law>
      <pubDate>Fri, 14 Jan 2022 00:00:00 +0530</pubDate>
      <guid isPermaLink="true">https://www.taxtmi.com/caselaws?id=417275</guid>
    </item>
  </channel>
</rss>